Oxigene Inc., of Waltham, Mass., passed an interim toxicity analysis in its Phase II trial of Zybrestat (fosbretabulin tromethamine) and bevacizumab for ovarian cancer. Patients were randomized to receive bevacizumab 15 mg/kg I.V. or bevacizumab plus fosbretabulin tromethamine 60 mg/m2 I.V.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter